L’utilisation du gemtuzumab ozogamicin (Mylotarg®) pour le traitement d’un cas de leucémie myéloïde aiguë réfractaire
Bibliographic record
Abstract
Resume La leucemie myeloide aigue (LMA) est une maladie qui touche environ 2,4 individus sur 100 000. Meme si le traitement conventionnel de la LMA peut entrainer des remissions chez 85 % des patients, la plupart des patients auront probablement une recidive de leur maladie. De plus, les taux de remission chez les patients plus âges qui ont fait une recidive sont decevants et demontrent le besoin d’evaluer d’autres options therapeutiques moins toxiques et tout a la fois efficaces. Le gemtuzumab ozogamicin (Mylotarg®), un anticorps monoclonal anti-CD33 humanise conjugue a la calicheamicin, represente une possibilite interessante chez les patients âges de plus de 60 ans. Trois etudes ouvertes ont evalue l’efficacite et l’innocuite du gemtuzumab ozogamicin chez les patients en premiere recidive. On retrouve un taux de reponse globale de 30 %, evaluee en fonction de la reponse complete et partielle, etant donne que la recuperation des plaquettes etait un facteur limitant. Les effets adverses rapportes durant la periode de traitement etaient surtout de grade 3 ou 4 et etaient retrouves jusqu’a 28 jours apres la deuxieme dose de gemtuzumab ozogamicin : neutropenie (97 %), thrombocytopenie (99 %) et anemie (47 %). Le cas d’un patient en cinquieme recidive de la leucemie myeloide aigue, chez qui le gemtuzumab ozogamicin a ete administre a raison de deux doses usuelles, est presente. Trois mois apres, il demontre une reponse partielle au traitement. Abstract Acute myeloid leukemia (AML) is a disease that affects about 2.4 individuals out of 100,000. Despite the fact that AML conventional therapy may achieve remission in 85% of patients, most of these patients will probably suffer from a relapse of their disease. Furthermore, in older patients who have suffered from a relapse, remission rates are deceiving. Other therapeutic options less toxic need to be evaluated. Gemtuzumab ozogamicin (Mylotarg®), an anti-CD33 humanized monoclonal antibody conjugated with calicheamicin, may represent an interesting option for patients over 60 years old. Three open trials have assessed the efficacy and safety of gemtuzumab ozogamicin in with a first relapse. The overall response rate is 30%, including both complete and partial responses, the latter including patients in whom platelet recovery is the limiting factor. The adverse reactions reported during the treatment period were of grade 3 or 4, and have occurred up to 28 days after the second dose of gemtuzumab ozogamicin. Those effects were neutropenia (97%), thrombocytopenia (99%), and anemia (47%). The case of a patient in fifth AML relapse, who has received two standard doses of gemtuzumab ozogamicin, is presented. A partial response is noted three months after treatment.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.000 | 0.000 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.000 | 0.000 |
| Bibliometrics | 0.000 | 0.000 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.000 | 0.000 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.000 | 0.001 |
| Insufficient payload (model declined to judge) | 0.001 | 0.000 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".